Ranolazine: Antianginal medicine or more?
Ranolazine, a piperazine derivative sold, is a well‐tolerated medication that selectively inhibits the late sodium current. It has beneficial metabolic properties and does not affect heart rate or blood pressure. Ranolazine is currently approved in the United States and Europe as a second‐line agent in the management of stable angina pectoris. In this review we showed that ranolazine is perspective medication for arrhythmia treatment.
How to cite this article:
Sergiy Fedorov. Ranolazine: Antianginal medicine or more?. Pharma Innovation 2017;6(3):232-234.